Studies related to Quality of Life and Low-FODMAP Diet

β-Galactooligosaccharide In Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms But Reduces Fecal Bifidobacteria

Effect None
Values IBS-related quality of life was unaffected.
Trial Design Randomized trial
Trial Length 2-4 Weeks
Number of Subjects 69
Sex n/a
Age Range 18-29, 30-44, 45-64
Body Types Overweight, Average
Notes for this study:
In this randomized, 3-arm controlled trial, 69 patients with IBS were assigned to a sham diet with placebo supplement (control), low-FODMAP diet with placebo (LFD), or a low-FODMAP diet plus 1.4g/day beta-galactooligosaccharide (a prebiotic) (LFD/B-GOS) for 4 weeks.

Gastrointestinal symptoms, fecal microbiota, short-chain fatty acids, and urine metabolites were anaylzed.

The low-FODMAP diet reduced Actinobacteria and butyrate. Though the addition of B-GOS to LFD produced greater improvements compared to the control group, B-GOS did not prevent the LFD-associated reduction in Bifidobacterium and did not produce greater results than LFD alone.
Funding issues for this study:
One author was supported by a doctoral research grant from Clasado Biosciences Ltd.. Another author received funding from the Almond Board of California and the International Nut and Dried Fruit Council. Another author received income or grants from AbbVie, Allergan, Ferring, Janssen, Napp, Takeda, and Tillotts. Another author consulted for Danone and received research funding from Clasado Biosciences, Danone, Nestec Ltd, the Almond Board of California, and the International Nut and Dried Fruit Council; this author is also the the coinventor of a low-FODMAP diet mobile app along with one other author (who also consulted for Danone and received funding from Clasado Biosciences, Ltd.)

Full details on all 9 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.